GENENTA SCIENCE(SP.ADR)/1 Aktie

View in Terminal

Loading quotes...

Forecast

Buy	1
Hold	0
Sell	0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last quarter, GENENTA SCIENCE(SP.ADR)/1 Aktie had revenue of €0 and net profit of -€2.68M

(EUR)	December 2025	YoY
Revenue	0	-
Gross profit	-14.04K	-
Net profit	-2.68M	-
EBITDA	-2.66M	-

Fundamentals

Metric	Value
Market capitalization	€16.13M
Number of shares	18.26M
52-week high/low	€2.31 - €0.49
Dividends	No
Beta	0.77
P/E ratio	-1.85
PEG ratio	-0.05
P/B ratio	0.59
P/S ratio	0.00

Company profile

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.